PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2017 February 21; 8(8): 14039–14049.
Published online 2016 October 9. doi:  10.18632/oncotarget.12538
PMCID: PMC5355160

Prostatic vascular damage induced by cigarette smoking as a risk factor for recovery after holmium laser enucleation of the prostate (HoLEP)

Abstract

Purpose

To evaluate the relationship between prostatic vessel changes induced by cigarette smoking and the perioperative outcome of holmium laser enucleation of the prostate (HoLEP).

Materials and Methods

A total of 268 postoperative patients with benign prostatic hyperplasia (BPH) were prospectively analysed in our department. They were divided into two groups (smokers and non-smokers) according to smoking history. Transrectal colour Doppler ultrasound was performed to evaluate the prostate vascular changes. Pathologically, HE staining, CD31 and CD34 were analysed in prostatic section chips. Furthermore, postoperative outcomes were determined during a 6-month follow-up period.

Results

The preoperative prostate volume was significantly decreased in smoking patients (P = 0.04). CPI was significantly lower in smoking BPH patients (P < 0.01), whereas RI was significantly increased in smokers compared with non-smokers (P < 0.01). Histological assays revealed elevated CD34 in the smoking BPH individuals presenting an increased number of microvessels. The HoLEP duration was increased in smokers. Interestingly, we identified significantly increased overactive bladder syndrome score (OABSS) and decreased Qmax in smoking individuals during the 6-month follow-up with no difference being observed preoperatively. However, no significant difference between the groups was observed for the International Prostate Symptom Score (IPSS).

Conclusions

The significantly lower CPI and higher RI values in smoking BPH patients indicated the presence of considerable vascular damage in these subjects. Moreover, cigarette smoking extended the surgical duration and prolonged the recovery period of overactive bladder (OAB) syndrome. Thus, integrated treatment should be suggested for various BPH individuals.

Keywords: benign prostatic hyperplasia, holmium laser enucleation of the prostate, smoking, vascular damage, perioperative characteristics

INTRODUCTION

Benign prostatic hyperplasia (BPH), one of the most common proliferative disorders in older males, is characterized by increasing tissue mass in prostatic transition zone. The pathogenic process of BPH involves various factors, including chronic inflammation, oxidative stress, hypoxia and ischaemia [1, 2]. These pathogenic factors may result in generalized or localized vessel disorder, which play significant role in BPH [3]. In a vicious circle, vascular damage also results in ischemia and hypoxia, which aggravates the disease progression [4, 5]. Although some researchers have argued that hypoxia and ischemia may accelerate cell proliferation and vascular damage may contribute to BPH [3], the anti-apoptotic effect is dependent on the severity and duration of anoxia [6, 7]. Thus, prostatic vascularity has always been a focus of studies about prostate enlargement.

Surgery is currently the most efficient treatment for BPH. Surgical methods have developed from an open method to transurethral endoscopic surgery. There is a growing emphasis on reducing the risk of surgery and accelerating postoperative recovery. However, local vessel changes in the prostate make performing surgery difficult and delay postoperative recovery. Although there have been numerous studies in the area of ischemia and BPH, little is known regarding the relationship between vessel damage and postoperative recovery.

Colour Doppler ultrasound (CDUS) is a non-invasive technology used to study blood flow. Computer-assisted quantification of CDUS by the calculation of colour pixel intensity (CPI) has been shown to be an accurate method to assess organ and tissue perfusion [8]. Pulsed-wave Doppler ultrasound is utilized to obtain the resistive index (RI), which represents both blood flow and pressure. RI represents one of the most relevant indicators of vascular injury in the evaluation of small prostatic vessels [9]. Pathologically, microvessel density (MVD) is identified using immunohistochemical staining for CD31 and CD34 [8, 10]. CD34 is expressed in pericytes of blood vessels standing mainly for the existing vessels, whereas CD31 is a pan-endothelial cell marker associated with newly formed microvessels [10].

It is widely accepted that cigarette smoking induces chronic inflammation, hypoxia and endothelial injury [1113]. Interestingly, numerous studies have reported that cigarette smoking reduces prostate volume, and some studies have even claimed that smoking delays BPH [1416], although other researchers held the opposite views in their own studies [17, 18]. However, the mechanism by which smoking induces prostatic vascular changes remains unknown. Furthermore, with surgery being the most efficient treatment for BPH, there is still no evidence for the relationship among chronic vascular disorders, smoking and perioperative characteristics.

The present study examined the relationship between cigarette smoking and prostatic vascular damage in BPH patients using contrast-enhanced CDUS and immunohistochemistry. We also evaluated the perioperative and follow-up data for smoking patients.

RESULTS

Data were obtained from 268 patients who underwent HoLEP during a 1-year period. The baseline characteristics of patients are listed in Table Table1.1. A slightly decreased prostate volume was observed in smoking patients (P = 0.04). The blood metabolic tests revealed that testosterone was significantly elevated in the smoking group (P < 0.01), whereas there were no significant differences in the other aspects, including serum PSA levels. CDUS data were collected preoperatively and divided into non-smoking vs. smoking groups according to the criteria. Interestingly, the vessel RI was significantly enhanced in the smoking group compared with the non-smoking group (P < 0.01). The results of the CPI are shown in Figure Figure1.1. It was significantly decreased in smoking patients (P < 0.01).

Table 1
Baseline pre- and post- operative characteristics
Figure 1
Representative images and analysis of RI and CPI in transrectal colour Doppler ultrasound on prostatic blood flow

The results of HE staining of the postoperative sections are displayed in Figure Figure22 demonstrating the presence of pathological prostatic hyperplasia in both groups. No obvious differences were observed between the two groups. Moreover, patients with prostatic cancer were excluded from our study according to the pathological analysis. The resected prostate chips were histologically examined for CD31 and CD34, ensuring variation of MVD. Although no significant differences in CD31 staining were observed, the smoking group exhibited stronger CD34 staining, suggesting an elevated MVD in this group (shown in Figure Figure22).

Figure 2
HE staining and immunohistochemical evaluation of prostatic tissue and brown-stained spots representing vessels at 100× magnification

The perioperative parameters were recorded and are listed in Table Table1.1. These parameters were similar in the two groups, except for a longer surgical duration (P = 0.04) in the smoking group. At the 6-month follow-up, the two groups did not significantly differ with respect to IPSS. Interestingly, the analysis of OABSS revealed a higher score for the smokers compared with the non-smokers in terms of 1-, 4- and 24-week postoperative data, although the preoperative scores of the two groups were similar. The variation curve of OABSS was shown in Figure Figure3.3. The Qmax and urinary volume were lower in the smoking group at the 4-week follow-up, whereas no differences between the groups were observed in the preoperative and 24-week follow-up data (shown in Table Table22).

Figure 3
Preoperative and postoperative OABSS curves at the 1-w, 4-w and 24-w follow-ups
Table 2
Follow-up data

Complications were reported during the 6-month follow-up period. One patient in the non-smoking group required recatheterization after catheter removal due to urine retention, whereas none of the patients in the smoking group required recatheterization. One non-smoking patient (vs. none in the smoking group) required a blood transfusion and reoperation for haemostasis. Various degrees of urinary incontinence were present in the postoperative patients, but this was resolved within 1 month after surgery. Posterior urethral strictures occurred in two patients and were resolved by internal urethrotomy. Bladder neck sclerosis was not observed in our study.

DISCUSSION

As is shown in Table Table3,3, some urologists explored the relationship between smoking and BPH [14, 16, 1930]. Some investigations have evaluated the relationship between smoking and BPH, demonstrating either a moderate inverse association between smoking and BPH or no association [14, 15, 26, 31, 32]. Other studies have reported a protective effect of smoking on BPH and prostatism [33]. In addition, the degree of cigarette smoking was associated with the persistence of the effects on the prostate: light or moderate smokers were less likely to have moderate to severe prostatism and BPH, whereas heavy smokers tended to have moderate to severe prostatism and BPH compared with non-smokers [16, 17]. Our results presented that the prostate volume was decreased in smokers compared with non-smokers (61.07±18.75 ml vs. 56.63±14.56 ml, P = 0.04). These findings suggest that cigarette smoking affects plasma steroid hormone levels, particularly by elevating testosterone concentrations. Higher plasma testosterone tends to be associated with higher intra-prostatic dihydrotestosterone (DHT) levels, which has been demonstrated to be important during the development of BPH [26, 34]. Moreover, nicotine has been shown to lead to DHT accumulation in the canine prostate and to increase sympathetic nervous system activity contributing to BPH and LUTS [26, 35]. In smokers with BPH, the cigarette tobacco composition and serum PH may also play a role in decreasing serum zinc levels, which has been reported to affect the amounts of both testosterone and DHT in the prostate [36]. Significantly elevated testosterone level was observed in our analysis, whereas no differences were observed in PSA levels or other metabolic factors. Thus, most studies have focused on the relationship between cigarette smoking and the pathological process of BPH. This report is the first study to investigate the effects of cigarette smoking on vascularity and perioperative characteristics.

Table 3
Previous studies on the relation between smoking and BPH

BPH, which is caused by an increased number of cells in the prostatic TZ, is also characterized by a change in vascularization. As a previous study reported, vascular damage and prostate cell proliferation share a common pathogenic mechanism. The vessel RI is low in healthy patients and is advanced in BPH patients. Some studies have attributed this finding to compressed arteries between the peripheral zone (PZ) and the TZ, resulting in a marked increase in the RI of the capsular arteries[37]. Other studies investigating the vascular anatomy of the normal prostate have found notable differences between the RI values of the PZ and TZ. These studies have reported significantly higher RI and lower CPI induced by diabetes in TZ but not in PZ [3]. In this study, we only analysed the CPI and RI in the TZ. We found that RI was significantly elevated smoking group compared with non-smokers (0.59 ± 0.05 vs. 0.65 ± 0.06, P < 0.01). Furthermore, decreased prostate volume was observed in the smokers after excluding the elevated compression from the enlarged PZ. These findings indicated significant vascular damage with increased vascular resistance in the smoking patients. CPI, as an analysis of tissue perfusion, confirmed the results that vessel damage resulted in poor organ perfusion of the prostate. Although CD34 showed the presence of increased microvessels in the prostates of smokers, organ hypoperfusion may still exist.

The detailed mechanism underlying these findings had not previously been clarified. Cigarette smoking, as is widely accepted, has been demonstrated to cause vascular injury via local hypoxia, oxidative stress, endothelial injury and chronic inflammation in different organs [3841]. In addition, vessel damage might cause the above adverse factors leading to a vicious circle. Moreover, damage of small vessels tends to result in organic or local ischemia. It has been reported that chronic prostatic vascular ischemia, hypoxia and chronic inflammation result in increased prostate volume[42]. However, these effects are dependent on the severity and duration. Severe ischemia triggered by the castration[43] of animals and the embolization of prostate vessels causes a reduced prostate[7, 44]. Elevated microvessel levels, as visualized by CD34, might be a compensatory effect, which cannot correct the hypoperfusion caused by the vascular damage. In addition, inflammatory factors and hypoxia have been shown to result in an increase in microvessels [45, 46] (Figure (Figure44).

Figure 4
Schematic model of the effects of smoking on prostate vascular and perioperative characteristics

Perioperative characteristics and follow-up data were also obtained during our prospective research. No significance was investigated between the two groups, except the operative time (81.13±11.51 vs. 84.63±13.42 h, P = 0.04). The increased operative duration in smokers might also result from the prolonged morcellation duration caused by structural changes, including stromal fibrosis and endothelial growth[42]. Although we developed the morcellation technique as previously reported, more time was still spent on the treatment of prostatic tissue, which consisted of more fibrosis[47]. Moreover, proliferating microvessels made it difficult to do enucleation and stop haemostasis during surgery. Thus, cigarette smoking tended to not affect surgical difficulty, except for a slightly extended surgical duration.

Defined as a score of more than 7 points on the IPSS, LUTS is commonly observed in BPH patients. As previously reported, there is controversy about the relationship between chronic smoking and LUTS[26]. Some researchers have argued that heavy smokers have a higher risk of LUTS compared to moderate smokers [17]. Many researchers have attributed this finding to nicotine, which increases sympathetic nervous system activity, the tone of the smooth muscle of the bladder and prostate, and testosterone levels [26]. The OABSS was developed to assess OAB syndrome, which can be caused by an obstruction due to BPH; OABSS is a useful tool for research and clinical practice [48]. Thus, we examined LUTS and OABSS in the follow-up study. In our analysis, no significant difference in IPSS was observed between smoking and non-smoking patients pre- or post- operatively. Moreover, OABSS showed no difference between the two groups preoperatively, which was consistent with results obtained in previous reports. Interestingly, the 1-w, 4-w, and 24-w postoperative follow-up studies revealed a significantly elevated OABSS in the smoking patients. This finding may be partly correlated with the relief of obstruction after surgery. The main syndrome before surgery was obstruction, which may present as LUTS and mask the OAB syndrome. After the enlarged prostate was removed, OAB syndrome was prominent. As some previous studies have reported, smoking may partially enhance the contractile activity of the urinary bladder, resulting in a decrease in postoperative urinary retention [49]. Furthermore, Qmax was evaluated in the outpatient follow-up procedure. The Qmax in the smoking group was significantly lower compared with the non-smokers (24.22±3.57 ml/s vs. 21.69±4.69 ml/s, P < 0.01) at the 4-w follow-up. However, the urinary volume was lower in the smoking patients, which may have been caused by OAB syndrome, resulting in a lower Qmax.

A major limitation of this study is that it did not elucidate the precise mechanism underlying cigarette smoking and prostate development. In addition, this study does not further our understanding of the prevention and treatment of vascular damage in BPH patients.

In conclusion, this prospective study demonstrated significantly lower CPI and higher RI values for smokers compared with non-smokers in BPH subjects, indicating considerable vascular damage in smoking BPH patients. Moreover, cigarette smoking slightly prolonged the operative duration and delayed OAB syndrome recovery. Thus, we recommend that BPH patients quit smoking preoperatively to improve their vascular damage, and medicine to improve OAB syndrome should be administered to thesepatients after surgery. Further studies should focus on the potential of integrated clinical treatment to decrease urinary complications and increase patient satisfaction.

MATERIALS AND METHODS

This prospective cohort comparison study has been performed at our medical centre from August 2015 to July 2016. In total, 268 patients treated at our hospital for lower urinary tract symptoms (LUTS) and obstruction due to BPH were included in the study. All of the patients underwent holmium laser enucleation of the prostate (HoLEP) due to urinary syndrome. Ethical approval was obtained, and written informed consent was obtained from the patients. Among the patients, 131 were non-smokers and 137 were cigarette smokers. The men who were enrolled in the study were asked to provide information, including age, weight, height, alcohol consumption, use of cigarettes, and medical history. The inclusion criteria were indications for the surgical treatment of BPH (eg, urinary retention, recurrent urinary tract infections, bladder stones or diverticula, treatment-resistant macroscopic haematuria, or dilatation of the upper urinary tract due to benign prostatic obstruction [BPO] with or without renal insufficiency)[50]. We excluded patients with severe pulmonary disease, heart disease, renal function impairment, any type of bleeding disorder, type 2 diabetes, hyperlipaemia, severe obesity (BMI ≥30 kg/m2), poor blood pressure control, alcohol consumption, neurogenic bladder dysfunction, bladder cancer, previous prostate surgery, PSA >4 ng/ml, prostate cancer, or urethral stricture. Smoking history was obtained during the interview, and the subjects were classified as smokers (patients who currently smoked more than 1 cigarette per day or had formerly smoked more than 100 cigarettes in their lifetime) or non-smokers (patients who had never smoked before). During the interview, patients with long-term alcohol consumption habits were excluded from the study. We categorized patients as drinkers if they drank alcohol more than once per week [26, 51].

Baseline characteristics consisting of urological history, concurrent diseases, previous drug therapy, International Prostate Symptom Score (IPSS), overactive bladder syndrome score (OABSS) and Qmax were collated prior to surgery. Preoperative blood tests, including PSA, serum sodium, haemoglobin and metabolic index, were also performed. All of the ultrasound investigations were performed before HoLEP by a single experienced radiologist and consisted of contrast-enhanced CDUS in which the RI was measured by pulsed-wave spectral Doppler analysis. Three to five waveforms of each of the participant's vessels were obtained, and the RIs from these waveforms were calculated to obtain the mean RI. The CPI values of transitional zones (TZs) were evaluated using computer-assisted quantification. We identified the region of interest as that with the highest detectable blood flow. ImageJ (1.46r; National Institutes of Health, USA) was utilized to post-process the output images. Details of the procedure that was followed were published by Berger, A. P. et al. in 2005 [3].

All the HoLEP procedures were performed by the same surgeon Zhong W. HoLEP was performed with a 550 m firing laser fibre and a 100 W continuous flow VersaPulse® holmium laser from Lumenis. A 27 Fr resectoscope with a modified bridge was used to hold the laser fibre (Storz, Tuttlingen, Germany). The power settings were 80-100 W at 2-1.5 J per second and 50-40 Hz. Transurethral morcellation was performed through a 26 Fr nephroscope using a mechanical morcellator (VersaCut™).

Postoperatively, we immediately assessed the serum sodium and haemoglobin levels, the operative time, and the resected prostatic weight. Catheterization time and hospitalization duration were also noted. Epidural anaesthesia and the lithotomy position were applied during surgery. The irrigation fluid (normal saline) was hung 60 cm above the operating table. An irrigating catheter was inserted and bladder irrigation was performed until haematuria was resolved. Catheter removal was dependent on urine colour without gross haematuria. Follow-up data were collected 1 week, 4 weeks and 24 weeks after surgery by a single experienced doctor. The data consisted of IPSS, OABSS and late postoperative complications. The surgical method and perioperative treatment were published by our group in 2012 [52].

The resected prostate mass was fixed in 10% buffered formalin, embedded in paraffin and stained with haematoxylin and eosin for pathological analyses. Next, the tissue chips were histologically analysed for CD31 and CD34 staining. After 30-min antigen fixation in a microwave, a blocking solution (1% BSA + 0.1% Tween-20 in PBS) was added. The slides were incubated overnight with an anti-CD31 antibody (Abcam, ab28364, USA) at the recommended concentration of 1:50, as well as with anti-CD34 (Abcam, ab81289, USA) at a concentration of 1:100. After four washes in blocking solution, the slides were incubated with a secondary antibody for 30 minutes, and the nuclei were counterstained with haematoxylin. Areas with the most intense vascularization were evaluated by scanning at 100× magnification. For each patient, three to five images were collected and analysed. Immunofluorescence intensity was quantified using ImageJ (1.46r; National Institutes of Health, USA).

Based on our research expenses and the study period, CDUS was performed on 102 smokers and 95 non-smokers. Tissue masses were collected from at least 40 patients in each group. Preoperative tests were performed for at least 115 patients in both groups. Our follow-up collection of IPSS and OABSS data included 105 non-smokers and 107 smokers; 24 patients were lost to follow-up. Similar to the Qmax and urinary volume analysis, preoperative data were collected from 114 non-smokers and 123 smokers. At least 105 patients from each group were selected for immunohistochemistry and HE staining. Data were recorded at 4 and 24 weeks during outpatient visits. Measurement data were statistically analysed using a two-tailed Student's t-test and are presented as the means ± SD. ANOVA was used to assess the variance in IPSS and OABSS during the 24-week follow-up. All statistical analyses were performed using a commercially available statistical package (SPSS 19.0; IBM). A p-value ≤0.05 was considered statistically significant.

Acknowledgments

This study was supported by grants from the Shanghai pudong new area health and family planning project (No.PW 2013D-3), key disciplines group construction project of pudong health bureau of shanghai (PWZxq2014-11) and the program for outstanding medical academic leader.

Footnotes

CONFLICTS OF INTERESTS

None of the authors declare competing financial interests.

REFERENCES

1. Vital P, Castro P, Ittmann M. Oxidative stress promotes benign prostatic hyperplasia. Prostate. 2015 doi: 10.1002/pros.23100. [PubMed] [Cross Ref]
2. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51:199–203. doi: 10.1016/j.eururo.2006.05.040. discussion 4-6. [PubMed] [Cross Ref]
3. Berger AP, Deibl M, Halpern EJ, Lechleitner M, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer A, Bartsch G, Frauscher F. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia. 2005;48:784–9. doi: 10.1007/s00125-005-1678-6. [PubMed] [Cross Ref]
4. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol. 2000;163:1725–9. [PubMed]
5. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev. 1998;7:869–73. [PubMed]
6. Sun F, Sanchez FM, Crisostomo V, Lima JR, Luis L, Garcia-Martinez V, Lopez-Sanchez C, Uson J, Maynar M. Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment—preliminary study in pigs. Radiology. 2008;246:783–9. doi: 10.1148/radiol.2463070647. [PubMed] [Cross Ref]
7. Jones P, Rai BP, Nair R, Somani BK. Current Status of Prostate Artery Embolization for Lower Urinary Tract Symptoms: Review of World Literature. Urology. 2015;86:676–81. doi: 10.1016/j.urology.2015.05.011. [PubMed] [Cross Ref]
8. Cheng WF, Lee CN, Chu JS, Chen CA, Chen TM, Shau WY, Hsieh CY, Hsieh FJ. Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma. Cancer. 1999;85:651–7. [PubMed]
9. Nelson TR, Pretorius DH. The Doppler signal: where does it come from and what does it mean? AJR Am J Roentgenol. 1988;151:439–47. doi: 10.2214/ajr.151.3.439. [PubMed] [Cross Ref]
10. Cheng SH, Liu JM, Liu QY, Luo DY, Liao BH, Li H, Wang KJ. Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis. Int J Clin Exp Pathol. 2014;7:5855–63. [PMC free article] [PubMed]
11. Penn DL, Witte SR, Komotar RJ, Sander Connolly E., Jr. The role of vascular remodeling and inflammation in the pathogenesis of intracranial aneurysms. J Clin Neurosci. 2014;21:28–32. doi: 10.1016/j.jocn.2013.07.004. [PubMed] [Cross Ref]
12. Liu M, Zhou C, Zheng J. Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition. Am J Transl Res. 2015;7:2026–35. [PMC free article] [PubMed]
13. Campesi I, Carru C, Zinellu A, Occhioni S, Sanna M, Palermo M, Tonolo G, Mercuro G, Franconi F. Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans. Am J Transl Res. 2013;5:497–509. [PMC free article] [PubMed]
14. Chyou PH, Nomura AM, Stemmermann GN, Hankin JH. A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy. Prostate. 1993;22:253–64. [PubMed]
15. Kupeli B, Soygur T, Aydos K, Ozdiler E, Kupeli S. The role of cigarette smoking in prostatic enlargement. Br J Urol. 1997;80:201–4. [PubMed]
16. Roberts RO, Jacobsen SJ, Rhodes T, Guess HA, Girman CJ, Panser LA, Chute CG, Oesterling JE, Lieber MM. Cigarette smoking and prostatism: a biphasic association? Urology. 1994;43:797–801. [PubMed]
17. Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Giovannucci E. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol. 1999;149:106–15. [PubMed]
18. Xu H, Fu S, Chen Y, Chen Q, Gu M, Wang Z. Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies. Medicine (Baltimore) 2016;95:e4565. doi: 10.1097/MD.0000000000004565. [PMC free article] [PubMed] [Cross Ref]
19. Fritschi L, Tabrizi J, Leavy J, Ambrosini G, Timperio A. Risk factors for surgically treated benign prostatic hyperplasia in Western Australia. Public Health. 2007;121:781–9. doi: 10.1016/j.puhe.2007.01.011. [PubMed] [Cross Ref]
20. Gass R. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int. 2002;90:649–54. [PubMed]
21. Kang D, Andriole GL, Van de Vooren RC, Crawford D, Chia D, Urban DA, Reding D, Huang WY, Hayes RB. Risk behaviours and benign prostatic hyperplasia. Bju International. 2004;93:1241–5. doi: 10.1111/j.1464-410X.2004.04839.x. [PubMed] [Cross Ref]
22. Kupeli B, Soygur T, Aydos K, Ozdiler E, Kupeli S. The role of cigarette smoking in prostatic enlargement. British Journal of Urology. 1997;80:201–4. doi: 10.1046/j.1464-410X.1997.00299.x. [PubMed] [Cross Ref]
23. Matzkin H, Cytron S, Simon D. Is there an association between cigarette smoking and gland size in benign prostatic hyperplasia? Prostate. 1996;29:42–5. doi: 10.1002/(sici)1097-0045(199607)29:1<42::aid-pros6>3.0.co;2-k. [PubMed] [Cross Ref]
24. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. Journal of Clinical Epidemiology. 2001;54:935–44. doi: 10.1016/s0895-4356(01)00351-1. [PubMed] [Cross Ref]
25. Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Giovannucci E. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. American Journal of Epidemiology. 1999;149:106–15. [PubMed]
26. Rohrmann S, Crespo CJ, Weber JR, Smit E, Giovannucci E, Platz EA. Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health And Nutrition Examination Survey. BJU Int. 2005;96:77–82. doi: 10.1111/j.1464-410X.2005.05571.x. [PubMed] [Cross Ref]
27. Sarma AV, Jacobson DJ, St. Sauver JL, Lieber MM, Girman CJ, Nehra A, Jacobsen SJ. Smoking and acute urinary retention: The Olmsted County study of urinary symptoms and health status among men. Prostate. 2009;69:699–705. [PMC free article] [PubMed]
28. Seitter WR, Barrett-Connor E. Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study. Am J Epidemiol. 1992;135:500–3. [PubMed]
29. Sidney S, Quesenberry C, Jr, Sadler MC, Lydick EG, Guess HA, Cattolica EV. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology. 1991;38:13–9. [PubMed]
30. Signorello LB, Tzonou A, Lagiou P, Samoli E, Zavitsanos X, Trichopoulos D. The epidemiology of benign prostatic hyperplasia: a study in Greece. BJU Int. 1999;84:286–91. [PubMed]
31. Prezioso D, Catuogno C, Galassi P, D'Andrea G, Castello G, Pirritano D. Life-style in patients with LUTS suggestive of BPH. Eur Urol. 2001;40(Suppl 1):9–12. [PubMed]
32. Haidinger G, Temml C, Schatzl G, Brossner C, Roehlich M, Schmidbauer CP, Madersbacher S. Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology. Eur Urol. 2000;37:413–20. [PubMed]
33. Roberts RO, Tsukamoto T, Kumamoto Y, Rhodes T, Masumori N, Miyake H, Girman CJ, Jacobsen SJ, Lieber MM. Association between cigarette smoking and prostatism in a Japanese community. Prostate. 1997;30:154–9. [PubMed]
34. Allen NE, Appleby PN, Davey GK, Key TJ. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control. 2002;13:353–63. [PubMed]
35. Meikle AW, Liu XH, Taylor GN, Stringham JD. Nicotine and cotinine effects on 3 alpha hydroxysteroid dehydrogenase in canine prostate. Life Sci. 1988;43:1845–50. [PubMed]
36. Taher MA, Saleh ES, Hassan SA, Essa MAA. Zinc, Copper Protein measurement in heavy smokers with Benign Prostatic Hyperplasia (BPH) International Journal of Pharmaceutical & Biological Research. 2012:187–90.
37. Tsuru N, Kurita Y, Masuda H, Suzuki K, Fujita K. Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol. 2002;9:427–30. [PubMed]
38. Huang YC, Chin CC, Chen CS, Shindel AW, Ho DR, Lin CS, Shi CS. Chronic Cigarette Smoking Impairs Erectile Function through Increased Oxidative Stress and Apoptosis, Decreased nNOS, Endothelial and Smooth Muscle Contents in a Rat Model. PLoS One. 2015;10:e0140728. doi: 10.1371/journal.pone.0140728. [PMC free article] [PubMed] [Cross Ref]
39. Jensen JA, Goodson WH, Hopf HW, Hunt TK. Cigarette smoking decreases tissue oxygen. Arch Surg. 1991;126:1131–4. [PubMed]
40. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol. 2007;5:276–92. [PubMed]
41. Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, Kitahara CM, Furr M, Li Y, Kemp TJ, Goedert JJ, Chang CM, Engels EA, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106:1–8. doi: 10.1093/jnci/dju294. [PMC free article] [PubMed] [Cross Ref]
42. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165:1019–26. [PubMed]
43. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate. 1998;36:201–6. [PubMed]
44. Lebdai S, Delongchamps NB, Sapoval M, Robert G, Amouyal G, Thiounn N, Karsenty G, Ruffion A, A de La Taille, Descazeaud A, Mathieu R. Early results and complications of prostatic arterial embolization for benign prostatic hyperplasia. World J Urol. 2015 doi: 10.1007/s00345-015-1665-6. [PubMed] [Cross Ref]
45. Ceyran AB, Senol S, Guzelmeric F, Tuncer E, Tongut A, Ozbek B, Savluk O, Aydin A, Ceyran H. Effects of hypoxia and its relationship with apoptosis, stem cells, and angiogenesis on the thymus of children with congenital heart defects: a morphological and immunohistochemical study. Int J Clin Exp Pathol. 2015;8:8038–47. [PMC free article] [PubMed]
46. Prevete N, Liotti F, Marone G, Melillo RM, de Paulis A. Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacol Res. 2015;102:184–91. doi: 10.1016/j.phrs.2015.09.017. [PubMed] [Cross Ref]
47. Chen Q, Chen YB, Wang Z, Peng YB, Zheng DC, Cai ZK, Li WJ, Zhou J. An improved morcellation procedure for holmium laser enucleation of the prostate. J Endourol. 2012;26:1625–8. doi: 10.1089/end.2012.0265. [PMC free article] [PubMed] [Cross Ref]
48. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology. 2006;68:318–23. doi: 10.1016/j.urology.2006.02.042. [PubMed] [Cross Ref]
49. Gandhi SD, Patel SA, Maltenfort M, Anderson DG, Vaccaro AR, Albert TJ, Rihn JA. Patient and surgical factors associated with postoperative urinary retention after lumbar spine surgery. Spine (Phila Pa. 1976);2014;39:1905–9. doi: 10.1097/brs.0000000000000572. [PubMed] [Cross Ref]
50. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ. European Association of U. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40. doi: 10.1016/j.eururo.2013.03.004. [PubMed] [Cross Ref]
51. Shiels MS, Rohrmann S, Menke A, Selvin E, Crespo CJ, Rifai N, Dobs A, Feinleib M, Guallar E, Platz EA. Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes Control. 2009;20:877–86. doi: 10.1007/s10552-009-9318-y. [PMC free article] [PubMed] [Cross Ref]
52. Chen YB, Chen Q, Wang Z, Peng YB, Ma LM, Zheng DC, Cai ZK, Li WJ, Ma LH. A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. J Urol. 2013;189:217–22. doi: 10.1016/j.juro.2012.08.087. [PubMed] [Cross Ref]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC